Telehealth firm LifeMD's Q3 revenue misses estimates

LifeMD

17/11/2025 21:14

Overview

LifeMD Q3 revenue grows 13% yr/yr but misses analyst expectations

Adjusted EBITDA for Q3 rises 20% yr/yr but misses analyst expectations

Company paid off all outstanding debt during the quarter

Outlook

LifeMD forecasts Q4 revenue between $45 mln and $46 mln

Company expects full-year 2025 revenue of $192 mln to $193 mln

LifeMD anticipates 2025 adjusted EBITDA of $13.5 mln to $14.5 mln

Result Drivers

TELEHEALTH GROWTH - Telehealth revenue increased 18%, contributing to overall revenue growth

PLATFORM DIVERSIFICATION - Co is diversifying its clinical platform with new launches in women's health, men's health, and psychiatry

WORKSIMPLI DIVESTITURE - Divestiture of WorkSimpli stake positions LifeMD as a pure-play telehealth and pharmacy platform

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Miss
$60.20 mln
$62.06 mln (8 Analysts)
Q3 EPS
-$0.10
Q3 Net Income
-$4.60 mln
Q3 Adjusted EBITDA
Miss
$5.10 mln
$6.06 mln (8 Analysts)
Q3 Gross Margin
88.00%


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

Wall Street's median 12-month price target for LifeMD Inc is $12.50, about 63% above its November 14 closing price of $4.63

The stock recently traded at 27 times the next 12-month earnings vs. a P/E of 60 three months ago

Press Release: ID:nGNX3dMDPF

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)